Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Cutting or masking transdermal patches is discouraged. Matrix patches can be cut if no licensed alternatives are available; reservoir patches should not be cut.
Practical guidance for safe application, monitoring, removal, disposal, documentation and storage of transdermal patches to reduce risk of medication errors.
These are the detailed and easy read summary reports of the northern pharmacy technical services (PTS) workforce project. They provide a critical analysis of the…
This audit document is intended to be used to audit Pharmacy aspects of the safe administration of intrathecal chemotherapy, as part of the EL(97)52 Audit…